Home
Conditions
Marginal Zone Lymphoma

Clinical trial condition

Marginal Zone Lymphoma

Explore clinical trials studying Marginal Zone Lymphoma. Study availability and eligibility vary by location and protocol.

114 public trials 41 recruiting studies

Refine in advanced search Browse all conditions

Marginal Zone Lymphoma trial results

Recruiting

Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma

NCT05846750

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: Institute of Hematology & Blood Diseases Hospital Tianjin, Tian, China

View Trial Details

Enrolling by Invitation

CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas

NCT07168486

Conditions: B-cell Lymphoma, Chronic Disease, Chronic Lymphocytic Leukemia, +31 more
Locations: University of Maryland, Baltimore Baltimore, Maryland, United States

View Trial Details

Not Yet Recruiting

Atrial Fibrillation Among Patients With Hematologic Malignancies on Tyrosine Kinase Inhibitor Therapy

NCT07711327

Conditions: Arrhythmias, Cardiac, Atrial Fibrillation, Atrial Fibrillation (AF), +35 more
Locations: City of Hope Duarte, California, United States

UC San Diego Health San Diego, California, United States

Stanford Health Care Stanford, California, United States

View Trial Details

Not Yet Recruiting

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

NCT07225439

Conditions: B-cell Non Hodgkin Lymphoma, Chronic Disease, Chronic Lymphocytic Leukemia, +30 more
Locations: Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center Cleveland, Ohio, United States

Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute Cleveland, Ohio, United States

View Trial Details

Not Yet Recruiting

Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma

NCT07609446

Conditions: Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
Locations: The First Affiliated Hospital of Soochow University Suzhou, Jiangsu, China

View Trial Details

Not Yet Recruiting

Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma

NCT07583810

Conditions: Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Extranodal Marginal Zone Lymphoma, Gastric Mucosa-Associated Lymphoid Tissue Lymphoma, +14 more
Locations: City of Hope Medical Center Duarte, California, United States

View Trial Details

Not Yet Recruiting

(CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)

NCT05923502

Conditions: Chronic Disease, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Diffuse Large B Cell Lymphoma, +27 more
Locations: Not specified

View Trial Details

Completed

ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

NCT05653271

Conditions: B-cell Lymphoma, Burkitt Lymphoma, DLBCL, +23 more
Locations: AdventHealth Orlando Orlando, Florida, United States

Emory University Atlanta, Georgia, United States

Indiana University Simon Comprehensive Cancer Center Indianapolis, Indiana, United States

Norton Cancer Institute Louisville, Kentucky, United States

View all 13 locations

View Trial Details

Completed

Preliminary Assessment of [18F]BL40 in PET/CT Scans

NCT06224309

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +33 more
Locations: BC Cancer Vancouver, British Columbia, Canada

View Trial Details

Completed

Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma

NCT05169658

Conditions: Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, +17 more
Locations: Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Marginal Zone Lymphoma

Marginal Zone Lymphoma trial results

Related conditions